share_log

RedHill Settles Movantik Patent Litigation With Aurobindo

RedHill Settles Movantik Patent Litigation With Aurobindo

Redhill Setting Movantik与Aurobindo提起专利诉讼
Benzinga Real-time News ·  2021/09/23 11:11
  • RedHill Biopharma Ltd (NASDAQ:RDHL) has announced a settlement and license agreement with Aurobindo Pharma USA Inc resolving their patent litigation in the U.S.
  • The litigation was related to Aurobindo's Abbreviated New Drug Application seeking approval by the FDA to market a generic version of Movantik (naloxegol).
  • RedHill acquired from AstraZeneca plc (NASDAQ:AZN) in April 2020 the global rights to Movantik, excluding Europe and Canada.
  • Under the settlement agreement terms, Aurobindo may not sell a generic version of Movantik in the U.S. until April 1, 2031.
  • Related: RedHill Unveils New Movantik Data For Opioid-Induced Constipation.
  • Price Action: RDHL stock is up 0.21% at $4.76 during the market session on the last check Thursday.
  • 红山生物医药有限公司(纳斯达克股票代码:RDHL)宣布与以下公司达成和解和许可协议Aurobindo Pharma USA Inc.解决他们在美国的专利诉讼。
  • 这起诉讼与Aurobindo的简化新药申请有关,该申请寻求FDA的批准,以销售Movantik(纳洛西戈)的仿制药。
  • Redhill于2020年4月从阿斯利康(纳斯达克股票代码:AZN)手中收购了Movantik的全球使用权,不包括欧洲和加拿大。
  • 根据和解协议条款,Aurobindo在2031年4月1日之前可能不会在美国销售仿制药Movantik。
  • 相关: Redhill公司公布治疗阿片类药物诱导便秘的新Movantik数据.
  • 价格行动:在周四最后一次检查的市场时段,RDHL股价上涨0.21%,至4.76美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发